Exxonmobil Investment Management Inc. TX Decreases Position in Zimmer Biomet Holdings, Inc. (ZBH)

Exxonmobil Investment Management Inc. TX lowered its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 13.5% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 38,635 shares of the medical equipment provider’s stock after selling 6,023 shares during the period. Exxonmobil Investment Management Inc. TX’s holdings in Zimmer Biomet Holdings were worth $4,961,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in ZBH. BlackRock Inc. raised its position in Zimmer Biomet Holdings by 4,042.4% in the first quarter. BlackRock Inc. now owns 16,740,383 shares of the medical equipment provider’s stock valued at $2,044,168,000 after buying an additional 16,336,262 shares in the last quarter. Nordea Investment Management AB raised its position in Zimmer Biomet Holdings by 25.0% in the first quarter. Nordea Investment Management AB now owns 4,931,281 shares of the medical equipment provider’s stock valued at $602,159,000 after buying an additional 987,398 shares in the last quarter. Glenview Capital Management LLC bought a new position in Zimmer Biomet Holdings during the first quarter valued at approximately $94,197,000. Point72 Asset Management L.P. raised its stake in shares of Zimmer Biomet Holdings by 230.3% in the first quarter. Point72 Asset Management L.P. now owns 1,053,500 shares of the medical equipment provider’s stock valued at $128,643,000 after buying an additional 734,500 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Zimmer Biomet Holdings by 3.7% in the first quarter. Vanguard Group Inc. now owns 13,041,411 shares of the medical equipment provider’s stock valued at $1,592,488,000 after buying an additional 464,916 shares during the period. 83.62% of the stock is currently owned by institutional investors.

Shares of Zimmer Biomet Holdings, Inc. (ZBH) opened at 111.70 on Friday. The firm has a market cap of $22.59 billion, a price-to-earnings ratio of 31.81 and a beta of 1.20. Zimmer Biomet Holdings, Inc. has a 12-month low of $95.63 and a 12-month high of $133.49. The firm has a 50-day moving average price of $124.93 and a 200 day moving average price of $121.26.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The firm had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.95 billion. During the same period last year, the company earned $2.02 EPS. The company’s revenue was up 1.1% on a year-over-year basis. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post $8.24 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be paid a $0.24 dividend. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 annualized dividend and a dividend yield of 0.86%. Zimmer Biomet Holdings’s dividend payout ratio is currently 27.59%.

WARNING: This piece was posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://transcriptdaily.com/2017/08/13/exxonmobil-investment-management-inc-tx-has-4-96-million-stake-in-zimmer-biomet-holdings-inc-zbh-updated-updated.html.

Several analysts recently issued reports on the stock. Morgan Stanley boosted their price objective on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a report on Monday, July 17th. Stifel Nicolaus reiterated a “hold” rating and set a $125.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Piper Jaffray Companies reiterated a “buy” rating and set a $141.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Canaccord Genuity reiterated a “buy” rating and set a $141.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Finally, Wells Fargo & Company reissued a “market weight” rating on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Four analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $136.90.

In related news, insider Sang Yi sold 17,731 shares of the stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $124.56, for a total transaction of $2,208,573.36. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Tony W. Collins sold 16,986 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The disclosure for this sale can be found here. Corporate insiders own 1.07% of the company’s stock.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply